Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Follicum has announced that the company's hair loss treatment projects are progressing according to plan and a patent application for an internally developed formulation of FOL-005 has been submitted. The cream formulation is intended to be lubricated into the scalp and has demonstrated good hair-stimulating effect in an animal model.

Follicum files patent application for new topical formulation for hair loss

The next step involves running a clinical Phase II study in alopecia patients, which is expected to start at the end of 2019. If granted, the patent application would extend the patent protection of FOL-005 by 8 years.

The new cream formulation has been developed In parallel with the clinical program of FOL-005. In previous clinical studies in alopecia patients, FOL-005 has been dosed by injecting a solution of the peptide locally, up to three times per week. In the first study, FOL-005 was injected into the thigh of healthy volunteers and in the second study, the peptide was injected onto the scalp of alopecia patients.

In both studies, positive effects on hair growth were demonstrated. The new formulation, which has been tested in an experimental animal model and showed good hair stimulating properties, will be studied in a new clinical study planned to begin at the end of 2019. Preparations for this study and discussions with authorities are currently underway. With the new formulation, it will be possible to study several different doses and increase the dosage frequency in a simple way, since the individual patient will take care of the treatment at home. This simplifies the study and means that the number of visits to the clinic during the study period will be minimized.

CEO Jan Alenfall comments: “We are very pleased to have developed a formulation of FOL-005 that the patient can use in a simple way. The challenges of developing functional topical formulations of peptides are to prevent the peptide from breaking down and to optimize the conditions for it to penetrate the skin. We have managed to meet these challenges with the new formulation which has a long shelf life and is easy and very attractive for the patient to use. This has given us the confidence to file a new patent application.”

Read More

Related news

Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

3 Apr 2019

New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.

Read more 
MedPharm's appointment with Destiny

MedPharm's appointment with Destiny

28 Mar 2019

Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more